Capricor to Present at the American Society of Gene and Cell Therapy’s 24th Annual Meeting
--Conference Session: Therapeutic Applications of Extracellular Vesicles: From Diagnostics to Drug Delivery--
LOS ANGELES, May 12, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Linda Marbán, Ph.D., Capricor’s CEO, will present at the American Society of Gene and Cell Therapy’s (ASGCT) 24th annual meeting, being held virtually May 11-14, 2021.
“We are honored to have been selected as an industry leader on exosome delivery for SARS-CoV-2 vaccinations. This premier international symposium is a key medical conference in our field and brings together the leading scientists and healthcare professionals focused on gene and cell therapies,” said Linda Marbán, Ph.D. – chief executive officer of Capricor.
|Session:||Therapeutic Applications of EVs: From Diagnostics to Drug Delivery|
|Title:||Exosome Delivery of SARS-CoV-2 Vaccines|
|Presenter:||Linda Marbán, Ph.D. – CEO of Capricor|
|Date:||May 13, 2021 (10:00 a.m. ET)|
Please visit the Investor Relations section of the Company website for archived webcasts and investor materials available at http://capricor.com/news/events/.
The mission of ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease. ASGCT’s strategic vision is to be a catalyst for bringing together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.
Details for the 2021 ASGCT virtual meeting are available on the meeting website at https://annualmeeting.asgct.org.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell- and exosome-based therapeutics and vaccines for the treatment and prevention of a broad spectrum of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing our exosomes platform technology as a next-generation therapeutic platform. Our current focus is on the development of exosomes loaded with nucleic acids, including mRNA, to treat or prevent a variety of diseases. For more information, visit www.capricor.com and follow the Company on Facebook, Instagram and Twitter.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of intellectual property rights; future royalty streams, revenue projections; expectations with respect to the expected use of proceeds from the recently completed offerings and the anticipated effects of the offerings; and any other statements about Capricor's management team's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended December 31, 2020 as filed with the Securities and Exchange Commission on March 15, 2021. All forward-looking statements in this press release are based on information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. None of Capricor’s exosome-based candidates have been approved for clinical investigation.
For more information, please contact:
LifeSci Advisors, LLC
AJ Bergmann, Chief Financial Officer
Released May 12, 2021